Merkel cell carcinoma: Evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - Implications for treatment with imatinib mesylate

Journal of Cutaneous Pathology

Volumn 34, Issue 4, 2007, Pages 324-329

  Swick, Brian L ^a   Ravdel, Larisa ^a   Fitzpatrick, James E ^a   Robinson, William A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MERKEL CELL TUMOR; ONCOGENE; SCHOOL CHILD;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, MERKEL CELL; CHILD; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 33947511415     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00613.x     Document Type: Article

References (37)

1. Toker C. Trabecular carcinoma of the skin. Arch Dermatol 1972; 105: 107.
2. Tang CK, Toker C. Trabecular carcinoma of the skin: an ultrastructural study. Cancer 1978; 42: 2311.
3. Gould VE, Moll R, Moll I, Lee I, Franke WW. Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms. Lab Invest 1985; 52: 334.
4. Hoefler H, Rauch H-J, Kerl H, Denk H. New immunocytochemical observations with diagnostic significance in cutaneous neuroendocrine carcinoma. Am J Dermatopathol 1984; 6: 525.
5. Walsh NM. Primary neuroendocrine (Merkel cell) carcinoma of the skin: morphologic and diversity implications thereof. Hum Pathol 2001; 32: 680.
6. Sibley RK, Dehner LP, Rosai J. Primary neuroendocrine (Merkel cell?) carcinoma of the skin. A clinicopathologic and ultrastructural study of 43 cases. Am J Surg Pathol 1985; 9: 95.
7. Wick MR, Goellner JR, Sceithauer BW, Thomas JR, Sanchez NP, Schroeter AL. Primary neuroendocrine carcinoma of the skin (Merkel cell tumors): a clinical, histologic, and ultrastructural study of thirteen cases. Am J Clin Pathol 1983; 79: 6.
8. Micali G, Ferraú F, Innocenzi D. Primary Merkel cell tumor: a clinical analysis of eight cases. Int J Dermatol 1993; 32: 345.
9. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 2003; 49: 832.
10. Allen PJ, Zhang Z-F, Coit DG. Surgical management of Merkel cell carcinoma. Ann Surg 1999; 229: 97.
11. Smith KJ, Skelton HG, Holland TT, Morgan AM, Lupton GP. Neuroendocrine (Merkel cell) carcinoma with intraepidermal component. Am J Dermatopathol 1993; 15: 528.
12. Brown HA, Sawyer DM, Woo T. Intraepidermal Merkel cell carcinoma with no dermal involvement. Am J Dermatopathol 2000; 22: 65.
13. Iacocca MV, Abernethy JL, Stefanato CM, Allan AE, Bhawan J. Mixed Merkel cell carcinoma and squamous cell carcinoma of the skin. J Am Acad Dermatol 1998; 39: 882.
14. Goessling W, McKee PH, Mayer RJ. Merkel cell carcinoma. J Clin Oncol 2002; 20: 588.
15. Su LD, Fullen DR, Lowe L, Uherova P, Schnitzer B, Valdez R. CD117 (KIT receptor) expression in Merkel cell carcinoma. Am J Dermatopathol 2002; 24: 289.
16. Strong S, Shalders K, Carr R, Snead DR. KIT receptor (CD117) expression in Merkel cell carcinoma. Br J Dermatol 2004; 150: 384.
17. Yang DT, Holden JA, Florell SR. CD117, CK20, TTF-1, and DNA topoisomerase 11-alpha antigen expression in small cell tumors. J Cutan Pathol 2004; 31: 254.
18. Feinmesser M, Halpern M, Kaganovsky E, et al. C-KIT expression in primary and metastatic Merkel cell carcinoma. Am J Dermatopathol 2004; 26: 458.
19. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal cell tumors that is more specific than CD 34. Mod Pathol 1998; 11: 728.
20. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal cell tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259.
21. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002; 346: 683.
22. von Mehren M. Targeted therapy with imatinib: hits and misses? J Clin Onccol 2005; 25: 8.
23. Penzel R, Aulmann S, Moock M, Schwarzbach M, Rieker RJ, Mechtersheimer G. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J Clin Pathol 2005; 58: 634.
24. Fenig E, Nordenberg J, Beery E, Sulkes J, Wasserman L. Combined effect of aloe-emodin and chemotherapeutic agents on the proliferation of an adherent variant cell line of Merkel cell carcinoma. Oncol Rep 2004; 11: 213.
25. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005; 13: 205.
26. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813.
27. Hartman K, Bruns SB, Henz BM. Mastocytosis: review of clinical and experimental aspects. J Invest Dermatol Symp Proc 2001; 6: 143.
28. Hibi K, Takahasi T, Sekido Y, et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991; 6: 2291.
29. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472.
30. van Oosterom AT, Judson I, Verweii J, et al. Safety and efficacy of imatinab (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001; 358: 1421.
31. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925.
32. Krystal GW, Honasawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000; 6: 3319.
33. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by thenovel tyrosine kinase inhibitor STI571. Oncogene 2000; 19: 2521.
34. Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005; 46: 35.
35. Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003; 9: 5880.
36. Grichnik JM, Ali WN, Burch JA, et al. KIT expression reveals a population of precursor melanocytes in human skin. J Invest Dermatol 1996; 106: 967.
37. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708.